116 related articles for article (PubMed ID: 16061642)
21. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma.
Hebert C; Norris K; Scheper MA; Nikitakis N; Sauk JJ
Mol Cancer; 2007 Jan; 6():5. PubMed ID: 17222355
[TBL] [Abstract][Full Text] [Related]
22. LMTK3 confers chemo-resistance in breast cancer.
Stebbing J; Shah K; Lit LC; Gagliano T; Ditsiou A; Wang T; Wendler F; Simon T; Szabó KS; O'Hanlon T; Dean M; Roslani AC; Cheah SH; Lee SC; Giamas G
Oncogene; 2018 Jun; 37(23):3113-3130. PubMed ID: 29540829
[TBL] [Abstract][Full Text] [Related]
23. Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms.
Harada-Shirado K; Ikeda K; Ogawa K; Ohkawara H; Kimura H; Kai T; Noji H; Morishita S; Komatsu N; Takeishi Y
Br J Haematol; 2015 Feb; 168(3):338-49. PubMed ID: 25236537
[TBL] [Abstract][Full Text] [Related]
24. Histone Deacetylase 10 Regulates the Cell Cycle G2/M Phase Transition via a Novel Let-7-HMGA2-Cyclin A2 Pathway.
Li Y; Peng L; Seto E
Mol Cell Biol; 2015 Oct; 35(20):3547-65. PubMed ID: 26240284
[TBL] [Abstract][Full Text] [Related]
25. The chromatin structuring protein HMGA2 influences human subtelomere stability and cancer chemosensitivity.
Ahmed SM; Ramani PD; Wong SQR; Zhao X; Ivanyi-Nagy R; Leong TC; Chua C; Li Z; Hentze H; Tan IB; Yan J; DasGupta R; Dröge P
PLoS One; 2019; 14(5):e0215696. PubMed ID: 31067275
[TBL] [Abstract][Full Text] [Related]
26. RAD50 targeting impairs DNA damage response and sensitizes human breast cancer cells to cisplatin therapy.
Flores-Pérez A; Rafaelli LE; Ramírez-Torres N; Aréchaga-Ocampo E; Frías S; Sánchez S; Marchat LA; Hidalgo-Miranda A; Quintanar-Jurado V; Rodríguez-Cuevas S; Bautista-Piña V; Carlos-Reyes A; López-Camarillo C
Cancer Biol Ther; 2014 Jun; 15(6):777-88. PubMed ID: 24642965
[TBL] [Abstract][Full Text] [Related]
27. MINA53 deficiency leads to glioblastoma cell apoptosis via inducing DNA replication stress and diminishing DNA damage response.
Xuan F; Huang M; Zhao E; Cui H
Cell Death Dis; 2018 Oct; 9(11):1062. PubMed ID: 30333481
[TBL] [Abstract][Full Text] [Related]
28. The high mobility group protein HMGA2: a co-regulator of chromatin structure and pluripotency in stem cells?
Pfannkuche K; Summer H; Li O; Hescheler J; Dröge P
Stem Cell Rev Rep; 2009 Sep; 5(3):224-30. PubMed ID: 19551524
[TBL] [Abstract][Full Text] [Related]
29. Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2.
Tessari MA; Gostissa M; Altamura S; Sgarra R; Rustighi A; Salvagno C; Caretti G; Imbriano C; Mantovani R; Del Sal G; Giancotti V; Manfioletti G
Mol Cell Biol; 2003 Dec; 23(24):9104-16. PubMed ID: 14645522
[TBL] [Abstract][Full Text] [Related]
30. Oncogene-triggered suppression of DNA repair leads to DNA instability in cancer.
Yaglom JA; McFarland C; Mirny L; Sherman MY
Oncotarget; 2014 Sep; 5(18):8367-78. PubMed ID: 25252808
[TBL] [Abstract][Full Text] [Related]
31. Decitabine augments cytotoxicity of cisplatin and doxorubicin to bladder cancer cells by activating hippo pathway through RASSF1A.
Khandelwal M; Anand V; Appunni S; Seth A; Singh P; Mathur S; Sharma A
Mol Cell Biochem; 2018 Sep; 446(1-2):105-114. PubMed ID: 29368096
[TBL] [Abstract][Full Text] [Related]
32. Cell-based high-throughput compound screening reveals functional interaction between oncofetal HMGA2 and topoisomerase I.
Peter S; Yu H; Ivanyi-Nagy R; Dröge P
Nucleic Acids Res; 2016 Dec; 44(22):e162. PubMed ID: 27587582
[TBL] [Abstract][Full Text] [Related]
33. Chaperoning HMGA2 protein protects stalled replication forks in stem and cancer cells.
Yu H; Lim HH; Tjokro NO; Sathiyanathan P; Natarajan S; Chew TW; Klonisch T; Goodman SD; Surana U; Dröge P
Cell Rep; 2014 Feb; 6(4):684-97. PubMed ID: 24508460
[TBL] [Abstract][Full Text] [Related]
34. Both XPA and DNA polymerase eta are necessary for the repair of doxorubicin-induced DNA lesions.
Moraes MC; de Andrade AQ; Carvalho H; Guecheva T; Agnoletto MH; Henriques JA; Sarasin A; Stary A; Saffi J; Menck CF
Cancer Lett; 2012 Jan; 314(1):108-18. PubMed ID: 21999933
[TBL] [Abstract][Full Text] [Related]
35. The HMGA proteins: a myriad of functions (Review).
Cleynen I; Van de Ven WJ
Int J Oncol; 2008 Feb; 32(2):289-305. PubMed ID: 18202751
[TBL] [Abstract][Full Text] [Related]
36. HMGA2 participates in transformation in human lung cancer.
Di Cello F; Hillion J; Hristov A; Wood LJ; Mukherjee M; Schuldenfrei A; Kowalski J; Bhattacharya R; Ashfaq R; Resar LM
Mol Cancer Res; 2008 May; 6(5):743-50. PubMed ID: 18505920
[TBL] [Abstract][Full Text] [Related]
37. Oncological role of HMGA2 (Review).
Zhang S; Mo Q; Wang X
Int J Oncol; 2019 Oct; 55(4):775-788. PubMed ID: 31432151
[TBL] [Abstract][Full Text] [Related]
38. ROS-dependent HMGA2 upregulation mediates Cd-induced proliferation in MRC-5 cells.
Xie H; Wang J; Jiang L; Geng C; Li Q; Mei D; Zhao L; Cao J
Toxicol In Vitro; 2016 Aug; 34():146-152. PubMed ID: 27071802
[TBL] [Abstract][Full Text] [Related]
39. Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2.
Yang E; Cisowski J; Nguyen N; O'Callaghan K; Xu J; Agarwal A; Kuliopulos A; Covic L
Oncogene; 2016 Mar; 35(12):1529-40. PubMed ID: 26165842
[TBL] [Abstract][Full Text] [Related]
40. Function of high-mobility group A proteins in the DNA damage signaling for the induction of apoptosis.
Fujikane R; Komori K; Sekiguchi M; Hidaka M
Sci Rep; 2016 Aug; 6():31714. PubMed ID: 27538817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
